Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short term Debt (2018 - 2023)

Historic Short term Debt for Akebia Therapeutics (AKBA) over the last 4 years, with Q4 2023 value amounting to $17.5 million.

  • Akebia Therapeutics' Short term Debt fell 4531.25% to $17.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $17.5 million, marking a year-over-year decrease of 4531.25%. This contributed to the annual value of $17.5 million for FY2023, which is 4531.25% down from last year.
  • As of Q4 2023, Akebia Therapeutics' Short term Debt stood at $17.5 million, which was down 4531.25% from $8.0 million recorded in Q3 2023.
  • In the past 5 years, Akebia Therapeutics' Short term Debt registered a high of $98.2 million during Q2 2022, and its lowest value of $8.0 million during Q3 2023.
  • Over the past 3 years, Akebia Therapeutics' median Short term Debt value was $32.0 million (recorded in 2022), while the average stood at $51.7 million.
  • The largest annual percentage gain for Akebia Therapeutics' Short term Debt in the last 5 years was 4531.25% (2023), contrasted with its biggest fall of 8786.9% (2023).
  • Quarter analysis of 3 years shows Akebia Therapeutics' Short term Debt stood at $97.5 million in 2021, then plummeted by 67.19% to $32.0 million in 2022, then plummeted by 45.31% to $17.5 million in 2023.
  • Its last three reported values are $17.5 million in Q4 2023, $8.0 million for Q3 2023, and $24.0 million during Q2 2023.